The increase in chloroquine levels associated with the CYP2C8*2 variant can potentially impact its tolerability, similar to what has been observed with amodiaquine in children from Zanzibar, where the CYP2C82 variant led to higher rates of dizziness and insomnia [10]. The gene discussed is CYP2C8; the disease is insomnia.